Rosecliff Acquisition I (MDAI) Return on Assets ROA from the second quarter of 2026 to second quarter of 2024 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Dec 31 2024 - CSIMarket
Rosecliff Acquisition I's ROA from the second quarter of 2026 to the second quarter of 2024 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Rosecliff Acquisition I's ROA in the second quarter of 2026?
Rosecliff Acquisition Corp I recorded a cumulative net loss of $-15 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -75.16%.
However, within the Healthcare sector 696 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4094, from total ROA ranking in the fourth quarter of 2025 at 4757.
IntroductionIn a recent development signaling its commitment to advancing medical diagnostics, Spectral AI (NASDAQ: MDAI) has announced significant software enhancements to its DeepView SnapShot M and DeepView AI-Burn systems targeted at improving diagnostic precision in wound care. These improvements, highlighted in a release on December 9, 2024, are the culmination of insights gained from frontline feedback from clinicians operating in critical care settings in the UK.Key Enhancements to Diagnostic SoftwareThe software updates were designed specifically to boost product performance and usability for healthcare professionals. By incorporating real-world experiences, Spectral AI aims to refine its technology, ensuring that clinicians have the tools necessary for making faster and more accurate treatment decisions. The commitment to utilizing clinician feedback is a notable aspect of Spectral AI s operational strategy, aimed at fostering innovation that is closely aligned with the needs of healthcare providers.
In a significant development for the healthcare sector, Spectral AI, Inc. (NASDAQ: MDAI), a pioneering artificial intelligence company focused on enhancing medical diagnostics for wound care, has reported a notable milestone in its U.S. Burn Pivotal Study. As of September 24, 2024, the company has successfully enrolled 25% of its target patient population at various emergency departments (EDs), reflecting a promising step forward in its clinical research efforts.The company has expanded its clinical trial footprint by adding two new ED sites, MedStar Washington Hospital Center in Washington, DC, under the guidance of Principal Investigator Dr. Shawn Tejiram, and the University of Utah, led by Principal Investigator Dr. Giavonni Lewis, MD, FACS. This expansion brings the total number of participating locations in the study to 11, thereby increasing the opportunity for patient enrollment and reinforcing Spectral AI s commitment to driving advancements in burn treatment.
Bridging the Gap: Spectral AI s DeepView System Seeks to Transform Burn Care Accessibility Amid Financial Headwinds In an era where technological advancements are reshaping the landscape of healthcare, Spectral AI, Inc. (Nasdaq: MDAI) is positioned at the forefront with its innovative DeepView AI-Burn system. Announced on September 17, 2024, the company s outlined regulatory strategy aims to facilitate the entry of this cutting-edge diagnostic tool into the U.S. market specifically for burn care indications. However, beneath this promising advancement lies a complex web of financial struggles that could complicate its mission to promote equitable access to essential burn treatment services. Recent financial disclosures reveal a troubling picture for Spectral AI. The company has recorded a cumulative net loss of $16 million for the year ending in the second quarter of 2024, resulting in a staggering return on assets (ROA) of -182.15%. This dismal performance stands in stark contrast to 516 other companies in the healthcare sector that have managed to achieve higher rates of return on assets during the same period. Moreover, the company’s total ranking has slipped dramatically from previous quarters, indicating systemic challenges that may hinder its operations and growth prospects.
Unequal Scars - Unpacking Access to Burn Care in Americann The recent American Burn Association study has revealed deep-rooted inequities in access to specialized burn care across the United States, highlighting a significant gap that leaves vulnerable populations without the life-saving treatment they need. As this crisis unfolds, innovative technology like Spectral AIs DeepView System proposes a solution, aiming to promote equitable access to burn care while simultaneously optimizing healthcare resources. However, the financial landscape for companies spearheading this change paints a complex picture. Spectral AI, a player in the healthcare technology sphere, is striving to innovate solutions that address the stark inequalities in burn care access. Their DeepView System is designed to enhance the diagnosis and treatment of burn injuries while ensuring that underserved communities benefit from high-quality care. As burn injuries often require immediate and specialized treatment, any delay can result in complications, further widening the health disparities that already plague the American healthcare system.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
